Bionomics IPO Presentation Deck
Legacy Oncology Asset Monetization to Drive Value: BNC101
Exclusive BNC101 Oncology License Agreement
for the Development of CAR-T Therapeutics
Bionomics
carina
biotech
Exclusive Agreement to license Bionomics' BNC 101 oncology
drug candidate to Carina Biotech for the development of
Chimeric Antigen Receptor T cell (CAR-T) therapy, which
harnesses the body's immune system to fight cancer.
Bionomics is eligible to receive up to A$118 million in clinical &
development milestones plus royalty payments if Carina fully
develops and markets the new therapy. In the event that
Carina sub-licenses the CAR-T treatment, Bionomics is eligible
to share in the sub-licensing revenues in early clinical
development and receive a substantial double-digit portion of
the revenues in later stages of clinical development.
In September 2021, Carina announced that it plans to initiate a
clinical trial of BNC101 CAR-T therapy for the treatment of
advanced colorectal (bowel) cancer in late 2022
Bionomics retains BNC 101 for other types of therapies
38View entire presentation